Collaboration, License, and Other Agreements - Other Collaboration and License Agreements (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Collaboration, License, Promotion and Other Commercial Agreements
Revenue		$ 108,637	$ 103,747	$ 303,397	$ 296,623
Research and development expense		11,545	10,907	33,819	38,554
Accrued research and development costs		5,673		5,673		$ 15,896
Collaborative arrangements revenue
Collaboration, License, Promotion and Other Commercial Agreements
Revenue		108,637	103,747	303,397	295,798
Alnylam | Collaborative arrangement, co-promotion agreements
Collaboration, License, Promotion and Other Commercial Agreements
Revenue		814	683	2,222	1,735
Alnylam | Royalty
Collaboration, License, Promotion and Other Commercial Agreements
Revenue		800	$ 700	2,200	$ 1,700
COUR Pharmaceuticals Development Company, Inc.
Collaboration, License, Promotion and Other Commercial Agreements
Collaborative arrangement, upfront payment	$ 6,000
Collaborative arrangement, contingent payment, payable	$ 13,500
Collaborative arrangement, option to acquire license, exercise price, payable		35,000		35,000
Collaborative arrangement, milestones. potential commercial milestone payments, term of agreement, payable		440,000		440,000
Research and development expense						19,500
Accrued research and development costs		$ 3,800		$ 3,800		$ 13,500